NGEN — NERVGEN PHARMA CORP.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1751912 ·
British Columbia, Canada
Last close
$1.96
Market Cap
$210.74M
52W High
$6.30
52W Low
$1.28
ADV30
631,669
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,196,618 | -29,217,233 | 90,190,914 | 86,789,698 | 72,913,623 |
| Mar 2026 | 0 | — | -7,531,578 | -1,675,549 | 20,765,547 | 16,559,056 | 15,223,975 |
| Dec 2025 | 0 | — | -6,404,283 | -26,908,856 | 23,209,641 | 22,069,635 | 19,732,715 |
| Sep 2025 | 0 | — | -6,170,687 | -4,156,070 | 13,077,452 | 11,364,055 | 16,019,155 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,647,717
Investing CF
$58,874
Financing CF
$98,663,069
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.60
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-177,656,300
Inventory
—
Receivables
$200,236
ST Investments
$0
EBIT TTM
$-30,177,102
Pretax Income TTM
$-22,034,686
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -25,079,252 | -44,117,305 | 23,209,641 | 19,732,715 | 3,476,926 | -19,499,211 |
| Dec 2024 | 0 | -25,176,149 | -24,250,049 | 19,486,223 | 16,909,616 | 2,576,607 | -16,841,034 |
| Dec 2023 | 0 | -17,776,710 | -22,382,120 | 13,236,021 | 15,245,126 | -2,009,105 | -11,295,594 |
| Dec 2022 | 0 | -23,025,033 | -20,722,283 | 23,875,217 | 10,414,137 | 13,461,080 | -17,784,163 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.34
Max Pain — expiry 2027-03-19
max pain strike: $2.50 · spot: $1.90 · call oi: 1,031 · put oi: 0
Expected Move to 2027-03-19:
±$1.03
(54.47%) —
implied range
$0.86 –
$2.93
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACIU | AC Immune SA | $209.79M | $2.11 | — |
| LAB | STANDARD BIOTOOLS INC. | $212.95M | $0.54 | — |
| PRLD | Prelude Therapeutics Inc | $216.05M | $3.32 | — |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $205.29M | $1.90 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $201.25M | $20.51 | — |
News headlines (Yahoo Finance, 1h cache)
NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer
2026-11-18 12:15 · Yahoo
NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-16 12:15 · Yahoo
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
2026-11-12 12:15 · Yahoo
NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury
2026-10-12 11:15 · Yahoo
NervGen to Host Inaugural R&D Day on September 30, 2026
2026-09-09 11:30 · Yahoo
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-13 11:30 · Yahoo
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
2026-05-26 11:15 · Yahoo
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
2026-05-22 03:27 · Yahoo
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-18 11:15 · Yahoo
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
2026-09-25 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.